clinical trial · NCT06857942
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Eli Lilly and Company·phase4·recruiting·n = 200
PsoriasisOverweight or ObesityTirzepatide
brief summary
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
started
Mar 19, 2025
primary completion
May 1, 2028
completion
May 1, 2028
last updated
Apr 17, 2026
official title
A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol